Live Breaking News & Updates on Geltex Pharmaceuticals
Stay updated with breaking news from Geltex pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jim Tananbaum, Founder and CEO of Foresite Capital, Announces $173 Million in Funds Raised for Foresite Labs Incubated Companies lapostexaminer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lapostexaminer.com Daily Mail and Mail on Sunday newspapers.
Carmichael Roberts, Sean O'Sullivan will share insights into climate tech and investing at Disrupt – TechCrunch techcrunch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from techcrunch.com Daily Mail and Mail on Sunday newspapers.
Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday. ....
Published: May 21, 2021 By Alex Keown Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation. ....
Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors News provided by Share this article Share this article SAN MATEO, Calif., May 3, 2021 /PRNewswire/ Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of Elizabeth Grammer, Esq., to its board of directors. Ms. Grammer brings to her role as director over 25 years of experience advising privately held and publicly traded life sciences companies at all stages of development. George Kemble, Ph.D., Sagimet s chief executive officer, said, Elizabeth is a strategic and innovative thinker with a passion for developing, articulating and leading the execution of corporate strategy and will be a great addition to our board. We look forward to leveraging her extensive experience to help Sagimet grow our business. ....